Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 8, 2013, Pages 442-451

  Frassetto, Lynda ^a   Floren, Leslie ^b   Barin, Burc ^c   Browne, Matthew ^b   Wolfe, Alan ^b   Roland, Michelle ^a   Stock, Peter ^a   Carlson, Laurie ^a   Christians, Uwe ^d   Benet, Leslie ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMMES CORPORATION   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

antiretrovirals; drug interactions; HIV; immunosuppressants; pharmacokinetics

Indexed keywords

CYCLOSPORIN; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; TACROLIMUS;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; GRAFT RECIPIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; OBSERVATIONAL STUDY;

ANTIRETROVIRALS; DRUG INTERACTIONS; HIV; IMMUNOSUPPRESSANTS; PHARMACOKINETICS;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEVIRAPINE; TACROLIMUS; YOUNG ADULT;

EID: 84886598875     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1860     Document Type: Article

References (26)

1. Frassetto L, Baluom M, Jacobsen W, et al,. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80: 13-17.
2. Frassetto L, Thai T, Aggarwal AM, et al,. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV + subjects. Drug Metab Pharmacokin 2003; 18: 114-120.
3. Vogel M, Voigt E, Michaelis HC, et al,. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-944.
4. Jain AK, Venkataramanan R, Shapiro R, et al,. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841-845.
5. Guaraldi G, Cocchi S, Codeluppi M, et al,. Pharmacokinetic interaction between amprenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006; 38: 1138-1140.
6. Jain AB, Venkataramanan R, Eghtesad B, et al,. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9: 954-960.
7. Kumar MS, Sierka DR, Damask AM, et al,. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67 (4): 1622-1629.
8. Mazuecos A, Pascual J, Gõmez E, et al,. Renal transplantation in HIV-infected patients in Spain. Nefrologia 2006; 26: 113-120.
9. Drug Interactions; cytochrome P450 System. 2003. http://medicine.iupui. edu/flockhart/table.htm [last accessed 25 March 2013].
10. Hariparsad N, Nallani S, Sane RS, Buckley DJ, Buckley AR, Desai PB,. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 1273-1281.
11. Wacher VJ, Wu C-Y, Benet LZ,. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-134.
12. Shugarts S, Benet LZ,. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009; 26: 2039-2054.
13. Cummins CL, Salphati L, Reid MJ, Benet LZ,. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003; 305: 306-314.
14. Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ,. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-1045.
15. Frassetto LA, Browne M, Cheng A, et al,. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816.
16. Christians U, Jacobsen W, Serkova N, et al,. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B 2000; 748: 41.
17. Sahin S, Benet LZ,. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 2008; 25: 2869-2877.
18. Physician's Desk Reference, 65rd edn. Physician's Desk Reference Inc: Montvale, NJ, 2011; 439-448, 2560-2568.
19. Stock PG, Barin B, Murphy B, et al,. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363 (21): 2004-2014.
20. Ma Q, Forrest A, Rosenkranz SL, et al,. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 2008; 29: 91-101.
21. Bramuglia GF, Cortada CM, Curras V, et al,. Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. J Pharm Sci 2009; 98: 327-336.
22. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al,. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005; 60: 378-389.
23. Jetter A, Fätkenheuer G, Frank D, et al,. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther 2010; 15: 975-983.
24. Christians U, Strom T, Zhang YL, et al,. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28: 39-44.
25. Floren LC, Bekersky I, Benet LZ, et al,. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-49.
26. http://www.hivtransplant.com [last accessed 25 March 2013].